Neuroendocrine tumours (NET) are rare. They usually arise from the gastrointestinal or bronchopulmonary systems. Most are discovered incidentally and the small bowel tumours pose special difficulty in detection and treatment. Primary mesenteric involvement is very rare. Here we report such a case with a liver metastasis. This was preoperatively diagnosed and treated by enucleation of the mesenteric tumour together with right hepatectomy in a single sitting.
DasariAShenCHalperinD, et al.Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol2017; 3: 1335–1342.
2.
BoudreauxJPKlimstraDSHassanMM, et al.The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas2010; 39: 753–766.
3.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: SEER 17 Regs Nov 2006 sub (1973Y2004). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistic Branch, 2006. Available at: www.seer.cancer.gov.
4.
WoodsideKJTownsendCMJrEversBM. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg2004; 8: 742–756.
5.
BarnardoDEStavrouMBourneR, et al.Primary carcinoid tumor of the mesentery. Hum Pathol1984; 15: 796–798.
6.
KarahanOIKahrimanGYikilmazA, et al.Gastrointestinal carcinoid tumors in rare locations: imaging findings. Clin Imaging2006; 30: 278–282.
7.
ParkISKyeBHKimHS, et al.Primary mesenteric carcinoid tumor. J Korean Surg Soc2013; 84: 114–117.
8.
YamanuhaJBallingerRCoonD, et al.Carcinoid tumor presenting as a primary mesenteric mass: a case report and review of the literature. Hawaii Med J2009; 68: 137–139.
9.
BerniniGPMorettiAFerdeghiniM, et al.A new human chromogranin ‘A’ immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer2001; 84: 636–642.
10.
BajettaEFerrariLMartinettiA, et al.Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer1999; 86: 858–865.
